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Abstract
Aims This study aimed to assess by a meta-analysis the clinical characteristics, all-cause and cardiovascular mortality, and
hospitalization of patients with heart failure (HF) with mid-range ejection fraction (HFmrEF) compared with HF with reduced
ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).
Methods and results Data from 12 eligible observational studies including 109 257 patients were pooled. HFmrEF patients
were signiﬁcantly different and occupied a mid-position between HFrEF and HFpEF: mean age 73.6 ± 9.8 vs. 72.6 ± 9.8 and
77.6 ± 7.2 years, male gender 59% vs. 68.5% and 40%, ischaemic heart disease 49% vs. 52.6% and 39.4%, hypertension
67.3% vs. 61.5% and 76.5%, atrial ﬁbrillation 45.2% vs. 39.6% and 46%, chronic obstructive pulmonary disease 26.4% vs.
24.9% and 30.5%, estimated glomerular ﬁltration rate 62 ± 30 vs. 63.3 ± 23 and 59 ± 22.5, use of renin–angiotensin system
inhibitors 79.6% vs. 90.1% and 68.7%, beta-blockers 82% vs. 89% and 73.5%, and aldosterone antagonists 20.3 vs. 31.5%
and 26%, P-values < 0.05. After a mean follow-up of 31 ± 5 months, all-cause mortality was signiﬁcantly lower in HFmrEF than
in HFrEF and HFpEF (26.8% vs. 29.5% and 31%): risk ratio (RR) 0.95 [0.93–0.98; 95% conﬁdence interval (CI)], P < 0.001, and
0.97 (0.94–0.99; 95% CI), P = 0.014, respectively. Cardiovascular mortality was lowest in HFmrEF (9.7% vs. 13% and 12.8%):
RR = 0.81 (0.73–0.91), P < 0.001, and 1.10 (0.97–1.24; 95% CI), P = 0.13, respectively. HF hospitalization in HFmrEF compared
to that in HFrEF and HFpEF was 23.9% vs. 27.6% and 23.3% with RR = 0.89 (0.85–0.93), P < 0.001, and RR = 1.12 (1.07–1.17),
P < 0.001, respectively.
Conclusions The results of this study support that HFmrEF is a distinct category characterized by a mid-position between
HFrEF and HFpEF and with the lowest all-cause and cardiovascular mortality.
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Introduction
During the last three decades, left ventricular systolic ejection
fraction (LVEF) has been used as the main diagnostic and
prognostic parameters in management of patients with
chronic heart failure (CHF). Reduced LVEF is generally associ-
ated with increased risk of overt heart failure (HF) and worse
prognosis, but the majority of randomized controlled trials
using therapeutic or mechanical interventions has been
restricted to CHF patients with LVEF <35%. Nonetheless, ob-
servational studies on patients with mildly reduced LVEF have
shown poorer prognosis compared with those with HF and
normal LVEF.1,2
Until recently, CHF patients have been classiﬁed into two
categories: HF with reduced ejection fraction (HFrEF) and
HF with preserved ejection fraction (HFpEF) based on LVEF
estimation with cut-off limits of ≤40% and ≥50%, respectively.
However, grey-area patients with moderately impaired LVEF
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have not been comprised in these traditional categories and
have been poorly characterized. Recently, more attention
has been given to patients with borderline low systolic LVEF,
whereas both the European Society of Cardiology and
American Society of Cardiology have introduced a new cate-
gory of CHF with borderline reduced LVEF of 40–49%, called
HF with mid-range ejection fraction (HFmrEF).3,4
Despite publication of a considerable number of epidemi-
ological studies and reviews on patients with HFmrEF com-
pared with HFrEF and HFpEF, the clinical characteristics and
prognosis of this newly suggested entity are still inade-
quately addressed and the results concerning mortality and
hospitalization have varied considerably across the published
studies.5–7 By means of a systematic review and meta-
analysis of the current literature, we collected and pooled
all available published data in order to shed more light on
patient characteristics, mortality, and hospitalization of
HFmrEF patients compared with the established categories
HFrEF and HFpEF.
Methods
Study design
This is a systematic literature review and meta-analysis,
which was conducted according to the Preferred Reporting
Items for Systematic Review and Meta-analysis.8
Search strategy
The search was conducted in the electronic databases
PubMed and Web of Science for all published clinical studies
that examined baseline characteristics and mortality in pa-
tients with HFmrEF compared with HFrEF and HFpEF. The fol-
lowing keywords in different combinations were used: heart
failure, left ventricle, ejection fraction combined with the
terms mid-range and borderline. All electronically published
papers were screened by titles and abstracts and by
reviewing the full paper if deemed relevant. The literature
search was restricted to papers published until 30 September
2017. The systematic search was supplemented by reviewing
all references in retrieved eligible studies, as well as key re-
view papers.
Study eligibility
Observational studies and randomized controlled trials were
considered for inclusion if they reported key baseline charac-
teristics and all-cause mortality in patients with HFmrEF (de-
ﬁned as LVEF of 40–49%) compared with HFrEF (deﬁned as
LVEF <40%) and HFpEF (deﬁned as LVEF ≥50%). The
diagnosis of HF categories should rely on the recent transtho-
racic echocardiographic ﬁndings and clinical judgement ac-
cording to the guidelines. Eligible studies were also required
to provide numbers of events for all-cause and cardiovascular
mortality, and preferably HF-speciﬁc hospitalization with a
follow-up period of at least 1 year. We excluded all studies
with a follow-up period shorter than 1 year, small-sized stud-
ies including <100 participants, and studies with insufﬁ-
ciently reported data.
Data extraction
We extracted data on the demographic features and key
baseline clinical variables reported as means or medians with
standard deviations (SD) or ranges from each study. We ex-
tracted absolute numbers for all-cause and cardiovascular
mortality and HF hospitalization. Values reported as medians
with ranges were re-estimated to their corresponding means
with SDs. Values presented as percentages were recalculated
to absolute numbers. In one study, 7 the death and hospital-
ization numbers were approximated from the Kaplan–Meier
curve. In case of studies lacking key data in published reports,
we contacted the corresponding authors to request the miss-
ing information. Two authors (J. A. and J. L.) conducted the
search and data extraction independently. Any disagreement
was resolved by consensus.
Statistical methods
Baseline characteristics were pooled and analysed as either
weighted means or numbers. The weighted mean difference
method was used for pooling of means and their SDs. The re-
ported numbers of all-cause and cardiovascular mortality and
HF hospitalization in eligible studies were pooled for the
HFmrEF vs. HFrEF and HFpEF groups, followed by an estima-
tion of a risk ratio (RR) with 95% conﬁdence interval (CI). De-
spite the signiﬁcant heterogeneity between studies, we used
a ﬁxed-effects model in order to maintain the real sizes of the
larger studies but beside that presented the results of
random-effects methods wherever reasonable. For the over-
all estimated RR, a P-value <0.05 was considered statistically
signiﬁcant. Heterogeneity among studies was tested using the
χ2 method (P-values <0.05 were considered statistically sig-
niﬁcant) and the I2 statistic. The I2 ranging between 0% and
100% indicated the percentage of variation in the study re-
sults attributable to between-study heterogeneity rather
than due to sampling error, and an I2 value >20% was consid-
ered statistically signiﬁcant. All analyses were performed
using the meta-analysis package of the statistic software pro-
gram STATA Version 13 (STATA Corporation, Lakeway Drive,
College Station, TX).
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Results
Twelve eligible observational studies were included in this
meta-analysis. The search process and outputs are shown in
Figure 1.
Study and patient characteristics
Study characteristics are shown in Table 1. The included stud-
ies were either registry or retrospective data analyses of pre-
viously conducted prospective trials. Of a total population of
109 257 patients, 51 496 (47.1%) had HFrEF, 20 114 (18.4%)
had HFmrEF, and 37 647 (34.4%) had HFpEF. Patients were
followed up for at least 12 months with a mean period of
31 ± 5 months.
Baseline characteristics of the three HF categories are re-
ported in Table 2. There were statistically signiﬁcant differ-
ences between HFmrEF and HFrEF and between HFmrEF
and HFpEF. Patients with HFmrEF were older than those with
HFrEF but younger than those with HFpEF. The proportion of
males and prevalence of ischaemic heart disease (IHD) among
HFmrEF were lower than those among HFrEF, but higher than
those among HFpEF. Hypertension was more frequent in pa-
tients with HFmrEF than in those with HFrEF, but less fre-
quent than in those with HFpEF. Diabetes was signiﬁcantly
less frequent in both HFmrEF and HFrEF than in HFpEF. Atrial
ﬁbrillation was more frequently present among HFmrEF than
among HFrEF but less frequent than among HFpEF. The prev-
alence of chronic obstructive pulmonary disease (COPD) was
highest in HFpEF relative to both HFrEF and HFmrEF. HFpEF
patients had also signiﬁcantly worse renal function than pa-
tients with HFrEF and HFmrEF. Angiotensin-converting en-
zyme inhibitors or angiotensin receptor blockers and beta-
blockers were more frequently used in HFrEF than in both
HFmrEF and HFpEF. Aldosterone antagonists were used more
frequently in patients with HFpEF than in both those with
HFrEF and HFmrEF.
Meta-analysis of risk of all-cause mortality
At the end of follow-up, patients with HFmrEF had lower all-
cause mortality 5402/20 114 (26.8%) than those with HFrEF
15 222/51 496 (29.5%) and those with HFpEF 11 681/37 647
(31.0%). Pooled data of the 12 studies using the ﬁxed-effects
model showed that the risk of all-cause death was signiﬁcantly
lower in patients with HFmrEF than in those with HFrEF with
RR = 0.95 (0.93–0.98; 95%CI), P < 0.001, and HFpEF with
RR = 0.97 (0.94–0.99; 95%CI), P = 0.020 (Figure 2. There was
signiﬁcant heterogeneity between the included studies,
P < 0.001 and I2 > 20%. Running the analysis using the
Figure 1 Flow chart of search process and results.
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random-effects model showed that the risk of all-cause death
was still signiﬁcantly lower in patients with HFmrEF than in
those with HFrEF with RR = 0.90 (0.83–0.98; 95% CI),
P = 0.010, but not signiﬁcant when compared with those with
HFpEF with RR = 1.01 (0.96–1.10; 95%CI), P = 0.59.
Data from ﬁve large size studies5,6,9–11 including 94 981 pa-
tients were also pooled to estimate 1 year all-cause mortality.
There were 14 078/46 126 (30.5%) deaths in HFrEF,
4876/16 936 (28.8%) in HFmrEF, and 10 740/31 919 (33.6%)
in HFpEF. Using the ﬁxed-effects model, the risk of all-cause
mortality in the ﬁrst year of follow-up was RR = 0.96 (0.94–
0.99; 95% CI), P = 0.013, and RR = 0.94 (0.91–0.97; 95%CI),
P < 0.001, comparing HFmrEF with HFrEF and HFpEF,
respectively.
A sensitivity analysis was performed by excluding the rela-
tively small study by Margolis et al.12 due its larger effect in
order to exclude the small-study effect. The results were un-
changed when comparing HFmrEF with HFrEF and HFpEF.
Meta-analysis of risk of cardiovascular death
Five studies provided data for cardiovascular death.6,7,11,13,14
There were 1229/9469 (13%) deaths among HFrEF patients,
365/3760 (9.7%) among HFmrEF patients, and 735/5739
(12.8%) among HFpEF patients. Meta-analysis using the
ﬁxed-effects model showed a signiﬁcant lower risk of death
in patients with HFmrEF than in those with HFrEF,
RR = 0.81 (0.73–0.91; 95% CI), but no signiﬁcant difference
when compared with HFpEF, RR = 1.10 (0.97–1.24; 95% CI)
(Figure 3). The results were unchanged using the random-
effects model.
Meta-analysis of risk of heart failure
hospitalizations
Five studies provided data for HF hospitalization.5–7,11,15
There were 6319/22 891 (27.6%) hospitalizations among
HFrEF patients, 2094/8769 (23.9%) among HFmrEF patients,
and 5445/2323 (23.3%) among HFpEF patients. When data
are pooled using the ﬁxed-effects model, the risk of hospital-
ization was signiﬁcantly lower in HFmrEF than in HFrEF
but higher in HFpEF, RR = 0.89 (0.85–0.93; 95% CI),
P < 0.001, and 1.12 (1.07–1.17; 95% CI), P < 0.001, respec-
tively (Figure 4). It was not relevant to repeat the analysis
using the random-effects model due to the large study effect.
All ﬁndings of the baseline characteristics, all-cause and
cardiovascular mortality, and hospitalization are summarized
in Figures 5 and 6.
Figure 2 Meta-analysis of all-cause mortality comparing heart failure (HF) with mid-range ejection fraction (HFmrEF) with HF with reduced ejection
fraction (HFrEF) and HF with preserved ejection fraction (HFPEF). CI, conﬁdence interval; RR, risk ratio.
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Figure 3 Meta-analysis of cardiovascular death comparing heart failure (HF) with mid-range ejection fraction (HFmrEF) with HF with reduced ejection
fraction (HFrEF) and HF preserved ejection fraction (HFPEF). CI, conﬁdence interval; RR, risk ratio.
Figure 4 Meta-analysis of heart failure (HF) hospitalization comparing heart failure with mid-range ejection fraction (HFmrEF) with HF with reduced
ejection fraction (HFrEF) and HF with preserved ejection fraction (HFPEF). CI, conﬁdence interval; RR, risk ratio.
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Discussion
Including recently published studies with substantial numbers
of patients in each CHF category, the results of this meta-
analysis demonstrated marked differences in key baseline
characteristics, all-cause and cardiovascular mortality, and
HF hospitalization between the three categories. Patients
with HFmrEF were older, less often male, and less frequently
had IHD compared with HFrEF patients. In contrast, HFmrEF
patients were younger, more often of male gender, and with
IHD compared with HFpEF patients. Baseline co-morbidities
such as hypertension, diabetes, and atrial ﬁbrillation were
more frequent in patients with HFmrEF than in those with
HFrEF but markedly less frequent in patients with HFpEF. Im-
portantly, renal function was worse, and there were more
COPD cases among patients with HFpEF than among those
with HFmrEF and HFrEF. As expected, use of the recom-
mended medications such as renin–angiotensin system inhib-
itors and beta-blockers was higher in patients with HFrEF and
in those with HFmrEF than in those with HFpEF. All-cause
mortality in the ﬁrst year and after approximately 3 years of
follow-up was lowest in HFmrEF. Similarly, cardiovascular
mortality was lower in HFmrEF than in both HFrEF and HFpEF
patients, while HF hospitalization was markedly lower in
HFmrEF than in HFrEF and slightly higher in HFmrEF than in
HFpEF. Overall, these epidemiological ﬁndings demonstrate
that the HFmrEF category occupies an intermediate position
between the two established categories concerning clinical
proﬁle and burden of co-morbidities, but meanwhile HFmrEF
is associated with the lowest mortality. These ﬁndings
Figure 5 Summary of the study ﬁndings illustrating the mid-positioning of heart failure (HF) with mid-range ejection fraction (HFmrEF) between HF
with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) concerning the key baseline characteristics. AF, atrial ﬁbrilla-
tion; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; IHD, ischaemic heart disease.
Figure 6 Summary of the study ﬁndings illustrating the mid-positioning of heart failure (HF) with mid-range ejection fraction (HFmrEF) between HF
with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) concerning the lower all-cause (AC) mortality at 1 year and
at the end of follow-up (mean 31 months), cardiovascular (CV) mortality, and HF hospitalization.
Characteristics and prognosis of HFmrEF 691
ESC Heart Failure 2018; 5: 685–694
DOI: 10.1002/ehf2.12283
strongly support that HFmrEF constitutes a distinct HF cate-
gory and with distinguished favourable prognosis.
It is well known that IHD is one of the major contributing
causes of death in CHF populations.16,17 The modifying role
of IHD in addition to the associated increased use of beta-
blockers on LVEF and mortality was well demonstrated in
the Swedish registry by Koh et al., included in this review.18
Accordingly, the improved survival and lower HF hospitaliza-
tions in the HFmrEF category, as compared with HFrEF, may
be explained by the lower prevalence of IHD. Compared with
HFpEF, the lower all-cause mortality can be explained by the
association of the markedly lower burden of co-morbidities,
younger age, and possibly excessive use of beta-blockers
and renin–angiotensin system blockers. Most likely, the
worse renal function and higher prevalence of COPD contrib-
uted considerably to the poorer prognosis of HFpEF patients,
despite the lower prevalence of IHD.19 The role of renal dys-
function as an independent predictor of mortality and the ef-
fect of its markedly high prevalence in HFpEF patients have
been previously described and currently demonstrated in
the Swedish registry.9 The higher prevalence of IHD and low
LVEF in HFrEF and the higher prevalence of hypertension, di-
abetes, and atrial ﬁbrillation in HFpEF patients may also ex-
plain the higher cardiovascular mortality in these two
categories as compared with HFmrEF.
Prognosis of CHF patients has been primarily linked with
the differences in LVEF as the traditional surrogate of progno-
sis despite the complex relationship between LVEF and
CHF.20 LVEF has been therefore used as a classiﬁcation tool
to categorize CHF patients. It has been also conﬁrmed that
the evidence-based management of these patients, particu-
larly of HFrEF, can reverse the unfavourable remodelling
and improve both LVEF and prognosis markedly.4 Thus, the
adverse effect of the remodelling process counteracted by
the improving effect of the contemporary therapies has pre-
sumably a decisive impact on LVEF dynamics and transition of
patients from one into another category.21 In this context, the
suggested concepts of whether HFmrEF constitutes a distinct
mid-position phenotype or whether HFmrEF is a transitional
phase between HFrEF and HFpEF are worth a debate and
further research. In the study by Tsuji et al.,7 the authors
examined the dynamic transition between the three CHF
categories over 3 years of follow-up and concluded that
HFrEF and HFmrEF change categories during follow-up and
concluded that HFmrEF represented a transitional status
between HFrEF and HFpEF rather than an independent entity.
However, a substantial part of HFmrEF patients maintained
their position. In contrast, HFpEF seemed to be a more stable
category in this study. Lacking similar data from the other
included studies on this issue makes it difﬁcult and too early
to determine which of the aforementioned concepts is
more plausible.
There is increasing evidence that a considerable number of
patients with HFrEF recover and improve their LVEF following
evidence-based treatment. This group of patients with im-
proved LVEF has been suggested to constitute a distinct cate-
gory called HF with improved EF (HFiEF).3 Patients with HFiEF
share in fact some key characteristics with HFmrEF patients
as they are more often younger females and of non-IHD ori-
gin unlike HFrEF patients, and this was pointed out in the
study by Junior et al.22 Thus, HFiEF patients, most likely after
a category transition, constitute a substantial part of patients
with HFmrEF beside those who have been stable and main-
tained their LVEF between 40% and 50% without deteriora-
tion.23 This LVEF improvement and category change may
explain the improved lower all-cause and cardiovascular mor-
tality in patients with HFmrEF compared with patients in the
other categories. On the other hand, HFpEF patients
whose LVEF deteriorates over time due to developing
myocardial infarction or inadequately treated cardiovascular
co-morbidities may consequently decline to a lower LVEF
category.21 As a result, it is most likely that HFmrEF is a
heterogeneous category comprising patients of different ori-
gins with different clinical proﬁles constituting a mixture of
subcategories, who can be classiﬁed as HFiEF, HF with stable
EF, and HF with worsened EF. However, more pathophysio-
logical research, prospective studies, and retrospective data
analyses are needed to consolidate these concepts.
Although LVEF is still considered as an important prognos-
tic surrogate and classiﬁcation tool of patients with CHF,
other well-investigated and relevant parameters have also
demonstrated great potential roles characterizing the syn-
drome of CHF. Circulating biomarkers such as brain natri-
uretic peptides, echocardiographically measured left atrial
size, and myocardial global longitudinal strain and size of
myocardial scar tissue measured by magnetic resonance im-
aging are similarly important prognostic predictors that may
guide management of CHF beyond LVEF. Accordingly, new
concepts based not solely on LVEF may aid prognosticating
and classiﬁcation of patients with CHF. In future studies, pos-
sibly, some of these measures may help to understand the
non-linear relation between LVEF and outcome in CHF.
Finally, the important clinical issue beside characterization
of HFmrEF patients may be the identiﬁcation of predictors of
deterioration and backward transition to the HFrEF category,
in order to prevent further worsening and to improve prog-
nosis. A number of the included studies in the current
meta-analysis examined the possible predictors of mortality
and effect of the medications used at baseline in patients
with HFmrEF.6,7,10,13,18 There was no consistency in their ﬁnd-
ings concerning age, gender, atrial ﬁbrillation, or hyperten-
sion. Interestingly, subanalyses of the prognostic impact of
medications used at baseline showed consistent mortality re-
duction by beta-blockers in patients with HFmrEF7,13,18; how-
ever, in the study by Koh et al.,18 this effect was limited to
patients with IHD. Because of the presence of IHD and cardio-
vascular co-morbidities, clinicians do treat HFmrEF patients
as HFrEF to some extent, but in the absence of randomized
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controlled trials, the evidence is still too weak to treat
HFmrEF patients as HFrEF guidelines recommend. It is not un-
likely that aldosterone antagonists, beta-blockers, and even
prophylactic ICD in subgroups of patients with HFmrEF may
improve their survival,2,24,25 but large-scale randomized con-
trolled trials are required to conﬁrm the beneﬁcial effect of
these therapies. Currently, circulating blood biomarkers and
various advanced cardiac imaging modalities can certainly
also contribute valuable knowledge in this ﬁeld and may
guide treatment.
Limitations
The included studies were of an observational nature, and
the investigated populations were heterogeneous concerning
the baseline characteristics and the size of prevalence of co-
morbidities. Another source of heterogeneity was due to
variation in sizes of the included studies, where few larger
studies imposed higher impact on the results. Thus, running
the mortality and hospitalization analyses in the ﬁxed-effects
model was more realistic. The overrepresentation of the
HFrEF population, which constituted almost half of the whole
analysed population, and the small number of the HFmrEF
population may not represent the community-based preva-
lence of the disease and may be attributed to imbalanced re-
cruitment and registration. Thus, compared with well-treated
populations in randomized controlled trials, the mortality
estimates may be higher and a time effect is possible. More-
over, some studies did not provide sufﬁcient data for analyses
of all baseline characteristics and co-morbidities. This study
accounted for the available key baseline characteristics and
did not include body mass index, anaemia, stroke, serum
brain natriuretic peptide, or HF-related echocardiographic pa-
rameters other than LVEF in the analyses. The analysis on HF
hospitalization and cardiovascular death as important end-
points may have lacked power because only ﬁve studies pro-
vided such data. Accordingly, the results of this study should
be interpreted cautiously.
Conclusions and perspectives
The results of this study support the notion of HFmrEF as a
distinct category that is characterized by a mid-position be-
tween HFrEF and HFpEF categories with respect to risk factor
proﬁle but is associated with the lowest all-cause and cardio-
vascular mortality. Despite the superior prognosis, a substan-
tial portion of HFmrEF patients still died of all and
cardiovascular causes after approximately 3 years of follow-
up, and the all-cause mortality was only slightly lower than
that in patients with HFrEF. These ﬁndings should encourage
more research on patient characterization, mortality predic-
tors, and effect of HF therapies to improve outcomes of pa-
tients with HFmrEF.
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